Nanostructured Lipid Carrier-mediated Transdermal Delivery System of Glibenclamide for Gestational Diabetes: Pharmacokinetic and Pharmacodynamic Evaluation

CONCLUSION: Transdermal patches incorporating NLCs hold promise for enhancing glibenclamide's therapeutic efficacy in GDM treatment. Improved skin permeation, sustained drug release, and enhanced bioavailability make NLC-based transdermal patches a potential alternative with better patient compliance.PMID:38213159 | DOI:10.2174/0115672018274038231212105440

Source: Current Drug Delivery - January 12, 2024 Category: Drugs & Pharmacology Authors: Ashwini M Preethi Sudheer Bharani S Sogali Source Type: research